| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Gyre Therapeutics, Inc. (GYRE) has 6 insiders with recent SEC Form 4 filings, including 0 buys and 24 sells. GYRE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 2.57M | $16.03M | - | |
| 10% | 2.14M | $13.40M | - | |
| CFO | 95.1K | $594.1K | - | |
| Dir | 52.0K | $325.0K | - | |
| CFO | 50.0K | $312.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 15, 2025 | Ma Songjiang84 | President | Sell | 4,000 | $10.62 | $42,480.00 | - | -23.1% | -29.6% | |
| Jan 13, 2025 | Ma Songjiang84 | President | Sell | 1,113 | $10.02 | $11,156.74 | - | -22.7% | -22.0% | |
| Jan 7, 2025 | Ma Songjiang84 | President | Sell | 2,216 | $10.08 | $22,336.06 | - | -23.7% | -26.9% | |
| Jan 3, 2025 | Ma Songjiang84 | President | Sell | 4,000 | $11.89 | $47,543.06 | - | -37.0% | -36.9% | |
| Dec 31, 2024 | Ma Songjiang84 | President | Sell | 4,000 | $12.40 | $49,600.00 | - | -36.2% | -41.7% | |
| Dec 27, 2024 | Ma Songjiang84 | President | Sell | 4,000 | $12.64 | $50,553.08 | - | -27.0% | -41.7% | |
| Dec 24, 2024 | Ma Songjiang84 | President | Sell | 4,000 | $12.10 | $48,399.20 | - | -22.6% | -39.6% | |
| Dec 20, 2024 | Ma Songjiang84 | President | Sell | 4,000 | $10.86 | $43,440.00 | - | -8.3% | -36.0% | |
| Dec 18, 2024 | Ma Songjiang84 | President | Sell | 4,000 | $11.21 | $44,851.78 | - | -19.9% | -31.3% | |
| Jun 28, 2024 | Usman Nassim67 | Director | Sale+OE | 3,452 | $12.00 | $41,437.81 | -67.8% | +7.3% | -37.8% |